Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma - Concepedia

Concepedia

Publication | Open Access

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

DOI Full Paper Access

27

Citations

28

References

2021

Year

Alexander M.M. Eggermont, Andrey Meshcheryakov, Victoria Atkinson, Christian U. Blank, Mario Mandalà, Georgina V. Long, Catherine Barrow, Anna Maria Di Giacomo, Rosalie Fisher, Shahneen Sandhu,

European Journal of Cancer

References

	Year	Citations

Page 1